Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Values Added Financial LLC

by · The Cerbat Gem

Values Added Financial LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 11.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 864 shares of the medical research company’s stock after selling 113 shares during the period. Values Added Financial LLC’s holdings in Thermo Fisher Scientific were worth $430,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Castle Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 2.8% in the first quarter. Castle Wealth Management LLC now owns 2,941 shares of the medical research company’s stock valued at $1,465,000 after acquiring an additional 80 shares during the period. North Capital Inc. acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at about $123,000. Rosenberg Matthew Hamilton raised its stake in Thermo Fisher Scientific by 42.4% in the 1st quarter. Rosenberg Matthew Hamilton now owns 937 shares of the medical research company’s stock valued at $466,000 after purchasing an additional 279 shares during the last quarter. Principal Financial Group Inc. raised its stake in Thermo Fisher Scientific by 1.0% in the 1st quarter. Principal Financial Group Inc. now owns 1,228,978 shares of the medical research company’s stock valued at $611,540,000 after purchasing an additional 12,063 shares during the last quarter. Finally, ZWJ Investment Counsel Inc. grew its holdings in Thermo Fisher Scientific by 3.5% in the 1st quarter. ZWJ Investment Counsel Inc. now owns 77,770 shares of the medical research company’s stock valued at $38,698,000 after buying an additional 2,618 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Up 1.5%

NYSE:TMO opened at $427.75 on Thursday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The stock has a market cap of $161.47 billion, a price-to-earnings ratio of 25.09, a PEG ratio of 2.24 and a beta of 0.77. The business has a fifty day moving average of $409.06 and a 200-day moving average of $481.30. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. During the same quarter last year, the business posted $5.11 earnings per share. The company’s quarterly revenue was up .2% on a year-over-year basis. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is 10.09%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president owned 23,167 shares of the company’s stock, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on TMO shares. Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, April 24th. UBS Group reduced their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Scotiabank cut their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating on the stock in a research report on Friday, April 25th. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Finally, The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Wednesday, April 23rd. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $604.05.

Get Our Latest Report on TMO

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).